AcelRx Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ACRX)

$1.90 +0.15 (+8.57 %)
(As of 02/19/2018 04:00 PM ET)
Previous Close$1.90
Today's Range$1.80 - $1.90
52-Week Range$1.55 - $5.75
Volume150,265 shs
Average Volume383,230 shs
Market Capitalization$95.64 million
P/E Ratio-1.70
Dividend YieldN/A
Beta2.64

About AcelRx Pharmaceuticals (NASDAQ:ACRX)

AcelRx Pharmaceuticals logoAcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.

Receive ACRX News and Ratings via Email

Sign-up to receive the latest news and ratings for ACRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:ACRX
CUSIPN/A
Phone+1-650-2163500

Debt

Debt-to-Equity Ratio-0.43%
Current Ratio4.78%
Quick Ratio4.71%

Price-To-Earnings

Trailing P/E Ratio-1.69642857142857
Forward P/E Ratio-1.79
P/E GrowthN/A

Sales & Book Value

Annual Sales$17.36 million
Price / Sales5.51
Cash FlowN/A
Price / CashN/A
Book Value($0.12) per share
Price / Book-15.83

Profitability

Trailing EPS($1.12)
Net Income$-43,150,000.00
Net Margins-374.76%
Return on EquityN/A
Return on Assets-58.74%

Miscellaneous

Employees39
Outstanding Shares50,340,000

AcelRx Pharmaceuticals (NASDAQ:ACRX) Frequently Asked Questions

What is AcelRx Pharmaceuticals' stock symbol?

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) issued its quarterly earnings data on Tuesday, August, 1st. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by $0.01. The specialty pharmaceutical company earned $2.66 million during the quarter, compared to analyst estimates of $2.63 million. View AcelRx Pharmaceuticals' Earnings History.

Where is AcelRx Pharmaceuticals' stock going? Where will AcelRx Pharmaceuticals' stock price be in 2018?

7 analysts have issued 1-year price objectives for AcelRx Pharmaceuticals' shares. Their predictions range from $2.00 to $14.00. On average, they expect AcelRx Pharmaceuticals' stock price to reach $6.83 in the next twelve months. View Analyst Ratings for AcelRx Pharmaceuticals.

What are Wall Street analysts saying about AcelRx Pharmaceuticals stock?

Here are some recent quotes from research analysts about AcelRx Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician's office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. " (1/23/2018)
  • 2. Stifel Nicolaus analysts commented, "Arc Logistics Partners LP reported 4Q16 Adjusted EBITDA of $13.9 million, below our estimate of $14.9 million, and distributable cash flow (DCF) of $11.0 million against our estimate of $11.1 million. Adjusted EBITDA came in below our estimates due to slightly lower revenues and higher operating expense on the quarter. Management provided an update on the ongoing Gulf LNG arbitration case and noted that the arbitration panel has heard the arguments and is in the process of rendering a decision. With that said, a timeline for a decision was not provided. On the call management highlighted their belief that the Gulf arbitration is acting as an overhang on ARCX units and expect a resolution to provide uplift to the partnership's valuation (assuming a positive outcome). Although we ultimately expect a favorable resolution for ARCX in the Gulf LNG arbitration, a full valuation and uncertainty over the outcome are keeping us on the sidelines. At this time we are maintaining our Hold rating." (3/14/2017)
  • 3. Royal Bank of Canada analysts commented, "ACRX reported 4Q results after the close where focus was primarily on the upcoming DSUVIA (ARX-04) launch, the expected AdCom meeting prior to approval, and progress with the Zalviso trial and the EU launch. We continue to view the story as on-track and make only minor adjustments to our model. We reiterate our Outperform rating and $6 PT." (3/3/2017)

Who are some of AcelRx Pharmaceuticals' key competitors?

Who are AcelRx Pharmaceuticals' key executives?

AcelRx Pharmaceuticals' management team includes the folowing people:

  • Adrian Adams, Independent Chairman of the Board (Age 64)
  • Richard A. King, President (Age 52)
  • Vincent J. Angotti, Chief Executive Officer (Age 48)
  • Raffi M. Asadorian, Chief Financial Officer (Age 47)
  • Pamela P. Palmer M.D. Ph.D., Chief Medical Officer, Director (Age 52)
  • Badri N. Dasu, Chief Engineering Officer (Age 52)
  • Lawrence G. Hamel, Chief Development Officer (Age 63)
  • Jane Wright-Mitchell, Chief Legal Officer (Age 46)
  • Richard F. Afable M.D., Director (Age 61)
  • Howard B. Rosen, Director (Age 59)

Who owns AcelRx Pharmaceuticals stock?

AcelRx Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (0.70%), Geller Family Office Services LLC (0.55%) and Virtu Financial LLC (0.12%). Company insiders that own AcelRx Pharmaceuticals stock include Howard B Rosen, Lawrence G Hamel, Life Sciences Maste Perceptive, Mark G Edwards, Pamela P Palmer, Perceptive Advisors Llc, Raffi Asadorian and Vincent J Angotti. View Institutional Ownership Trends for AcelRx Pharmaceuticals.

Who sold AcelRx Pharmaceuticals stock? Who is selling AcelRx Pharmaceuticals stock?

AcelRx Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. Company insiders that have sold AcelRx Pharmaceuticals company stock in the last year include Lawrence G Hamel and Life Sciences Maste Perceptive. View Insider Buying and Selling for AcelRx Pharmaceuticals.

Who bought AcelRx Pharmaceuticals stock? Who is buying AcelRx Pharmaceuticals stock?

AcelRx Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Geller Family Office Services LLC and Virtu Financial LLC. Company insiders that have bought AcelRx Pharmaceuticals stock in the last two years include Howard B Rosen, Mark G Edwards, Pamela P Palmer, Raffi Asadorian and Vincent J Angotti. View Insider Buying and Selling for AcelRx Pharmaceuticals.

How do I buy AcelRx Pharmaceuticals stock?

Shares of AcelRx Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AcelRx Pharmaceuticals' stock price today?

One share of AcelRx Pharmaceuticals stock can currently be purchased for approximately $1.90.

How big of a company is AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals has a market capitalization of $95.64 million and generates $17.36 million in revenue each year. The specialty pharmaceutical company earns $-43,150,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis. AcelRx Pharmaceuticals employs 39 workers across the globe.

How can I contact AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals' mailing address is 351 Galveston Dr, REDWOOD CITY, CA 94063-4736, United States. The specialty pharmaceutical company can be reached via phone at +1-650-2163500 or via email at [email protected]


MarketBeat Community Rating for AcelRx Pharmaceuticals (ACRX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  270 (Vote Outperform)
Underperform Votes:  197 (Vote Underperform)
Total Votes:  467
MarketBeat's community ratings are surveys of what our community members think about AcelRx Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AcelRx Pharmaceuticals (NASDAQ:ACRX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.572.572.572.71
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.83$6.83$6.83$8.25
Price Target Upside: 279.63% upside279.63% upside279.63% upside175.00% upside

AcelRx Pharmaceuticals (NASDAQ:ACRX) Consensus Price Target History

Price Target History for AcelRx Pharmaceuticals (NASDAQ:ACRX)

AcelRx Pharmaceuticals (NASDAQ:ACRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/27/2017HC WainwrightReiterated RatingBuy$5.00N/AView Rating Details
10/13/2017Piper Jaffray CompaniesReiterated RatingHold$2.00N/AView Rating Details
10/13/2017Royal Bank of CanadaLower Price TargetOutperform -> Outperform$6.00 -> $5.00N/AView Rating Details
10/13/2017Jefferies GroupDowngradeBuy -> HoldN/AView Rating Details
10/12/2017Roth CapitalSet Price TargetBuy$8.00N/AView Rating Details
8/9/2017Stifel NicolausUpgradeHold -> BuyHighView Rating Details
8/1/2017CowenReiterated RatingHoldHighView Rating Details
5/6/2016Seaport Global SecuritiesUpgradeAccumulate -> BuyN/AView Rating Details
4/14/2016Janney Montgomery ScottInitiated CoverageNeutralN/AView Rating Details
(Data available from 2/19/2016 forward)

Earnings

AcelRx Pharmaceuticals (NASDAQ:ACRX) Earnings History and Estimates Chart

Earnings by Quarter for AcelRx Pharmaceuticals (NASDAQ:ACRX)

AcelRx Pharmaceuticals (NASDAQ ACRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($0.26)($0.28)$2.46 million$1.49 millionViewN/AView Earnings Details
8/1/2017Q2 2017($0.28)($0.29)$2.63 million$2.66 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.28)($0.34)$2.36 million$3.11 millionViewListenView Earnings Details
3/2/2017Q4 2016($0.23)($0.21)$3.05 million$6.44 millionViewListenView Earnings Details
11/1/2016Q316($0.23)($0.25)$2.89 million$1.60 millionViewN/AView Earnings Details
7/28/2016Q216($0.22)($0.24)$2.17 million$4.53 millionViewListenView Earnings Details
5/2/2016Q1 2016($0.22)($0.22)$2.05 million$3.03 millionViewN/AView Earnings Details
3/7/2016Q415($0.10)($0.24)$4.97 million$1.73 millionViewListenView Earnings Details
10/29/2015Q315($0.23)$0.11$1.75 million$13.90 millionViewListenView Earnings Details
8/3/2015Q215($0.26)($0.20)$0.30 million$1.92 millionViewListenView Earnings Details
5/4/2015Q115($0.28)($0.27)$0.40 million$0.18 millionViewN/AView Earnings Details
3/9/2015Q4 2014($0.33)($0.32)$0.23 millionViewN/AView Earnings Details
11/10/2014Q4 2014($0.33)($0.32)$4.95 million$4.83 millionViewN/AView Earnings Details
8/11/2014Q214($0.27)($0.34)$0.20 million$0.07 millionViewN/AView Earnings Details
5/8/2014Q114($0.23)($0.22)$0.28 million$0.10 millionViewN/AView Earnings Details
3/3/2014Q413($0.17)($0.18)$4.93 million$27.60 millionViewN/AView Earnings Details
11/5/2013Q313($0.19)($0.26)$0.40 million$0.55 millionViewN/AView Earnings Details
8/12/2013Q2 2013($0.22)($0.22)$1.73 million$0.41 millionViewListenView Earnings Details
5/8/2013Q1 2013($0.26)($0.34)$0.68 million$0.94 millionViewN/AView Earnings Details
3/12/2013Q4 2012($0.39)($0.41)ViewN/AView Earnings Details
11/6/2012Q312($0.38)($0.38)ViewN/AView Earnings Details
8/9/2012Q2 2012($0.39)($0.35)ViewN/AView Earnings Details
5/8/2012Q1 2012($0.35)($0.36)ViewN/AView Earnings Details
3/20/2012Q4 2011($0.39)($0.33)ViewN/AView Earnings Details
11/8/2011Q3 2011($0.34)($0.30)ViewN/AView Earnings Details
8/11/2011Q2 2011($0.32)($0.25)ViewN/AView Earnings Details
5/12/2011Q1 2011($0.22)($0.30)ViewN/AView Earnings Details
3/24/2011Q4 2010($5.23)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

AcelRx Pharmaceuticals (NASDAQ:ACRX) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.06 EPS
Next Year EPS Consensus Estimate: $-1.06 EPS

Dividends

Dividend History for AcelRx Pharmaceuticals (NASDAQ:ACRX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

AcelRx Pharmaceuticals (NASDAQ ACRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 28.10%
Institutional Ownership Percentage: 14.03%
Insider Trades by Quarter for AcelRx Pharmaceuticals (NASDAQ:ACRX)
Institutional Ownership by Quarter for AcelRx Pharmaceuticals (NASDAQ:ACRX)

AcelRx Pharmaceuticals (NASDAQ ACRX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/14/2017Mark G EdwardsDirectorBuy30,000$1.90$57,000.00150,000View SEC Filing  
11/13/2017Raffi AsadorianCFOBuy5,000$1.94$9,700.0012,000View SEC Filing  
10/2/2017Lawrence G HamelInsiderSell10,161$5.29$53,751.6916,379View SEC Filing  
9/11/2017Raffi AsadorianCFOBuy7,000$3.24$22,680.007,000View SEC Filing  
8/24/2017Mark G EdwardsDirectorBuy5,000$3.02$15,100.00115,200View SEC Filing  
8/24/2017Vincent J AngottiCEOBuy15,000$3.00$45,000.0015,000View SEC Filing  
8/22/2017Pamela P. PalmerInsiderBuy10,000$2.95$29,500.00View SEC Filing  
6/19/2017Life Sciences Maste PerceptiveMajor ShareholderSell875,000$2.40$2,100,000.00View SEC Filing  
9/29/2016Perceptive Advisors LlcMajor ShareholderSell216,500$3.92$848,680.00View SEC Filing  
9/15/2016Perceptive Advisors LlcMajor ShareholderSell392,850$3.70$1,453,545.00View SEC Filing  
5/13/2016Howard B RosenCEOBuy10,206$3.26$33,271.5650,000View SEC Filing  
5/12/2016Mark G EdwardsDirectorBuy15,000$3.15$47,250.00105,000View SEC Filing  
11/18/2015Perceptive Advisors LlcMajor ShareholderSell176,200$5.35$942,670.00View SEC Filing  
11/6/2015Perceptive Advisors LlcMajor ShareholderSell92,100$4.59$422,739.00View SEC Filing  
9/9/2015Perceptive Advisors LlcMajor ShareholderSell310,000$4.18$1,295,800.00View SEC Filing  
5/7/2015Mark G EdwardsDirectorBuy40,000$3.13$125,200.00View SEC Filing  
3/10/2014Mark WanDirectorSell1,000,000$12.35$12,350,000.00View SEC Filing  
11/7/2013Perceptive Advisors Llcmajor shareholderBuy200,000$6.51$1,302,000.00View SEC Filing  
11/4/2013Perceptive Advisors Llcmajor shareholderBuy155,000$6.87$1,064,850.00View SEC Filing  
11/1/2013Perceptive Advisors LlcMajor ShareholderBuy360,660$6.91$2,492,160.60View SEC Filing  
9/20/2013Guy NohraDirectorSell158,153$10.59$1,674,840.27View SEC Filing  
9/18/2013Guy NohraDirectorSell128,780$10.42$1,341,887.60View SEC Filing  
7/23/2013Perceptive Advisors LlcMajor ShareholderBuy850,000$11.65$9,902,500.00View SEC Filing  
6/6/2013Mark G EdwardsDirectorBuy10,000$8.10$81,000.00View SEC Filing  
5/28/2013Adrian AdamsDirectorBuy75,000$8.19$614,250.00View SEC Filing  
12/7/2012Mark A WanDirectorBuy2,416,918$3.31$7,999,998.58View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

AcelRx Pharmaceuticals (NASDAQ ACRX) News Headlines

Source:
DateHeadline
AcelRx Pharmaceuticals to Present at 2018 RBC Capital Markets Global Healthcare ConferenceAcelRx Pharmaceuticals to Present at 2018 RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - February 16 at 8:17 AM
Jefferies Group Weighs in on AcelRx Pharmaceuticals Incs FY2019 Earnings (ACRX)Jefferies Group Weighs in on AcelRx Pharmaceuticals Inc's FY2019 Earnings (ACRX)
www.americanbankingnews.com - February 15 at 3:10 PM
Brokers Offer Predictions for AcelRx Pharmaceuticals Incs FY2022 Earnings (ACRX)Brokers Offer Predictions for AcelRx Pharmaceuticals Inc's FY2022 Earnings (ACRX)
www.americanbankingnews.com - February 14 at 4:14 PM
AcelRx Pharmaceuticals Inc (ACRX) Receives Average Rating of "Hold" from AnalystsAcelRx Pharmaceuticals Inc (ACRX) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - January 26 at 5:38 PM
Zacks: Analysts Expect AcelRx Pharmaceuticals Inc (ACRX) Will Announce Quarterly Sales of $2.90 MillionZacks: Analysts Expect AcelRx Pharmaceuticals Inc (ACRX) Will Announce Quarterly Sales of $2.90 Million
www.americanbankingnews.com - January 25 at 3:44 AM
AcelRx Pharmaceuticals (ACRX) Downgraded to "Hold" at Zacks Investment ResearchAcelRx Pharmaceuticals (ACRX) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 23 at 5:28 PM
AcelRx Pharmaceuticals (ACRX) Upgraded to "Buy" at Zacks Investment ResearchAcelRx Pharmaceuticals (ACRX) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - January 16 at 5:24 PM
Zacks Investment Research Downgrades AcelRx Pharmaceuticals (ACRX) to HoldZacks Investment Research Downgrades AcelRx Pharmaceuticals (ACRX) to Hold
www.americanbankingnews.com - January 15 at 4:28 PM
Zacks: Brokerages Anticipate AcelRx Pharmaceuticals Inc (ACRX) Will Post Quarterly Sales of $2.90 MillionZacks: Brokerages Anticipate AcelRx Pharmaceuticals Inc (ACRX) Will Post Quarterly Sales of $2.90 Million
www.americanbankingnews.com - January 8 at 4:40 PM
Zacks: Analysts Expect AcelRx Pharmaceuticals Inc (ACRX) Will Announce Earnings of -$0.20 Per ShareZacks: Analysts Expect AcelRx Pharmaceuticals Inc (ACRX) Will Announce Earnings of -$0.20 Per Share
www.americanbankingnews.com - January 6 at 11:28 AM
How to Short a Stock - BenzingaHow to Short a Stock - Benzinga
www.benzinga.com - January 4 at 5:20 AM
AcelRx Pharmaceuticals Inc’s (NASDAQ:ACRX) Earnings Declined -16.55%, But How Did It Fare Against The Industry?AcelRx Pharmaceuticals Inc’s (NASDAQ:ACRX) Earnings Declined -16.55%, But How Did It Fare Against The Industry?
finance.yahoo.com - January 3 at 3:16 PM
AcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: Q3, 2017 By the Numbers : January 3, 2018AcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: Q3, 2017 By the Numbers : January 3, 2018
finance.yahoo.com - January 3 at 11:20 AM
AcelRx Pharmaceuticals Inc (ACRX) Given Average Recommendation of "Hold" by BrokeragesAcelRx Pharmaceuticals Inc (ACRX) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 1 at 8:14 PM
AcelRx Stock Looks Weak Ahead Of Revised NDA Submissions For Two Products - Seeking AlphaAcelRx Stock Looks Weak Ahead Of Revised NDA Submissions For Two Products - Seeking Alpha
seekingalpha.com - December 30 at 3:16 PM
AcelRx Pharmaceuticals (ACRX) Upgraded to "Buy" by Zacks Investment ResearchAcelRx Pharmaceuticals (ACRX) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - December 27 at 5:00 PM
Comparing AcelRx Pharmaceuticals (ACRX) & Nantkwest (NK)Comparing AcelRx Pharmaceuticals (ACRX) & Nantkwest (NK)
www.americanbankingnews.com - December 24 at 11:52 PM
Zacks: Analysts Expect AcelRx Pharmaceuticals Inc (ACRX) to Post -$0.21 EPSZacks: Analysts Expect AcelRx Pharmaceuticals Inc (ACRX) to Post -$0.21 EPS
www.americanbankingnews.com - December 21 at 1:14 AM
AcelRx Pharmaceuticals, Inc. (ACRX) Receives Consensus Recommendation of "Hold" from AnalystsAcelRx Pharmaceuticals, Inc. (ACRX) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - December 7 at 7:44 PM
$2.90 Million in Sales Expected for AcelRx Pharmaceuticals, Inc. (ACRX) This Quarter$2.90 Million in Sales Expected for AcelRx Pharmaceuticals, Inc. (ACRX) This Quarter
www.americanbankingnews.com - December 5 at 10:26 AM
AcelRx Pharmaceuticals, Inc. (ACRX) Expected to Post Earnings of -$0.21 Per ShareAcelRx Pharmaceuticals, Inc. (ACRX) Expected to Post Earnings of -$0.21 Per Share
www.americanbankingnews.com - December 3 at 5:38 AM
Breakfast Technical Briefing on Medical Equipment Stocks -- Intuitive Surgical ...Breakfast Technical Briefing on Medical Equipment Stocks -- Intuitive Surgical ...
www.prnewswire.com - November 20 at 10:02 PM
AcelRx Pharma (ACRX) Announces Publishing of Manuscript ... - StreetInsider.comAcelRx Pharma (ACRX) Announces Publishing of Manuscript ... - StreetInsider.com
www.streetinsider.com - November 16 at 3:40 PM
AcelRx Pharmaceuticals Reports Publication of Manuscript Analyzing Sufentanil Sublingual Tablets in Patients with Postoperative PainAcelRx Pharmaceuticals Reports Publication of Manuscript Analyzing Sufentanil Sublingual Tablets in Patients with Postoperative Pain
finance.yahoo.com - November 16 at 10:43 AM
FY2017 EPS Estimates for AcelRx Pharmaceuticals, Inc. Boosted by Analyst (ACRX)FY2017 EPS Estimates for AcelRx Pharmaceuticals, Inc. Boosted by Analyst (ACRX)
www.americanbankingnews.com - November 16 at 5:50 AM
Mark G. Edwards Acquires 30,000 Shares of AcelRx Pharmaceuticals, Inc. (ACRX) StockMark G. Edwards Acquires 30,000 Shares of AcelRx Pharmaceuticals, Inc. (ACRX) Stock
www.americanbankingnews.com - November 15 at 10:20 AM
 Brokerages Expect AcelRx Pharmaceuticals, Inc. (ACRX) Will Announce Earnings of -$0.21 Per Share Brokerages Expect AcelRx Pharmaceuticals, Inc. (ACRX) Will Announce Earnings of -$0.21 Per Share
www.americanbankingnews.com - November 14 at 7:16 PM
AcelRx Pharmaceuticals, Inc. (ACRX) Given Average Rating of "Hold" by AnalystsAcelRx Pharmaceuticals, Inc. (ACRX) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - November 12 at 8:13 PM
AcelRx Pharmaceuticals, Inc. (ACRX) Short Interest UpdateAcelRx Pharmaceuticals, Inc. (ACRX) Short Interest Update
www.americanbankingnews.com - November 11 at 3:40 AM
AcelRx Pharmaceuticals (ACRX) CEO Vince Angotti on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaAcelRx Pharmaceuticals' (ACRX) CEO Vince Angotti on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 10 at 8:10 AM
Edited Transcript of ACRX earnings conference call or presentation 9-Nov-17 9:30pm GMTEdited Transcript of ACRX earnings conference call or presentation 9-Nov-17 9:30pm GMT
finance.yahoo.com - November 10 at 8:10 AM
AcelRx Pharmaceuticals reports 3Q lossAcelRx Pharmaceuticals reports 3Q loss
finance.yahoo.com - November 9 at 9:31 PM
AcelRx Pharma (ACRX) Reports Publication of Manuscript ... - StreetInsider.comAcelRx Pharma (ACRX) Reports Publication of Manuscript ... - StreetInsider.com
www.streetinsider.com - November 9 at 4:23 PM
AcelRx Pharmaceuticals Reports Publication of Manuscript Evaluating Sufentanil Sublingual Tablets for Moderate-to-Severe Acute Pain in the Emergency DepartmentAcelRx Pharmaceuticals Reports Publication of Manuscript Evaluating Sufentanil Sublingual Tablets for Moderate-to-Severe Acute Pain in the Emergency Department
finance.yahoo.com - November 9 at 4:23 PM
AcelRx Pharmaceuticals, Inc. to Host Earnings CallAcelRx Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 4:23 PM
AcelRx Pharmaceuticals Reports Third Quarter 2017 Financial ResultsAcelRx Pharmaceuticals Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 4:23 PM
Investor Expectations to Drive Momentum within Mosaic, Baker Hughes, Acelrx Pharma, Ciena, Exelon, and SM Energy – Discovering Underlying Factors of InfluenceInvestor Expectations to Drive Momentum within Mosaic, Baker Hughes, Acelrx Pharma, Ciena, Exelon, and SM Energy – Discovering Underlying Factors of Influence
finance.yahoo.com - November 6 at 4:12 PM
AcelRx Pharmaceuticals to Hold Third Quarter 2017 Financial Results Conference Call and Webcast on Thursday ... - PR Newswire (press release)AcelRx Pharmaceuticals to Hold Third Quarter 2017 Financial Results Conference Call and Webcast on Thursday ... - PR Newswire (press release)
www.prnewswire.com - October 30 at 8:33 PM
AcelRx Pharmaceuticals to Hold Third Quarter 2017 Financial Results Conference Call and Webcast on Thursday, November 9thAcelRx Pharmaceuticals to Hold Third Quarter 2017 Financial Results Conference Call and Webcast on Thursday, November 9th
finance.yahoo.com - October 30 at 8:33 PM
ETFs with exposure to AcelRx Pharmaceuticals, Inc. : October 30, 2017ETFs with exposure to AcelRx Pharmaceuticals, Inc. : October 30, 2017
finance.yahoo.com - October 30 at 3:31 PM
Why AcelRx Pharmaceuticals Inc’s (ACRX) Ownership Structure Is ImportantWhy AcelRx Pharmaceuticals Inc’s (ACRX) Ownership Structure Is Important
finance.yahoo.com - October 30 at 3:31 PM
AcelRx Pharmaceuticals, Inc. (ACRX) Expected to Announce Quarterly Sales of $2.46 MillionAcelRx Pharmaceuticals, Inc. (ACRX) Expected to Announce Quarterly Sales of $2.46 Million
www.americanbankingnews.com - October 27 at 10:40 AM
AcelRx Pharmaceuticals, Inc. (ACRX) Receives "Buy" Rating from HC WainwrightAcelRx Pharmaceuticals, Inc. (ACRX) Receives "Buy" Rating from HC Wainwright
www.americanbankingnews.com - October 27 at 9:22 AM
Analyzing Versartis (VSAR) & AcelRx Pharmaceuticals (ACRX)Analyzing Versartis (VSAR) & AcelRx Pharmaceuticals (ACRX)
www.americanbankingnews.com - October 26 at 11:37 AM
AcelRx Pharmaceuticals (ACRX) & Its Peers Critical AnalysisAcelRx Pharmaceuticals (ACRX) & Its Peers Critical Analysis
www.americanbankingnews.com - October 25 at 11:34 PM
AcelRx Pharmaceuticals, Inc. (ACRX) Set to Announce Earnings on MondayAcelRx Pharmaceuticals, Inc. (ACRX) Set to Announce Earnings on Monday
www.americanbankingnews.com - October 23 at 6:00 AM
AcelRxs DSUVIA™ Clinical Trial Results Selected as a "Top Abstract" for Oral Presentation at ASAs Annual Meeting - ANESTHESIOLOGY® 2017AcelRx's DSUVIA™ Clinical Trial Results Selected as a "Top Abstract" for Oral Presentation at ASA's Annual Meeting - ANESTHESIOLOGY® 2017
finance.yahoo.com - October 20 at 3:36 PM
AcelRx Pharmaceuticals, Inc. (ACRX) Given Average Rating of "Hold" by BrokeragesAcelRx Pharmaceuticals, Inc. (ACRX) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - October 18 at 10:42 PM
Your Daily Pharma Scoop: ACRX Second Chance, AERI Rhopressa Success, Aratana ENTYCE Launch - Seeking AlphaYour Daily Pharma Scoop: ACRX Second Chance, AERI Rhopressa Success, Aratana ENTYCE Launch - Seeking Alpha
seekingalpha.com - October 16 at 8:55 PM
SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of AcelRx Pharmaceuticals, Inc. - Business Wire (press release)SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of AcelRx Pharmaceuticals, Inc. - Business Wire (press release)
www.businesswire.com - October 16 at 8:55 PM

SEC Filings

AcelRx Pharmaceuticals (NASDAQ:ACRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AcelRx Pharmaceuticals (NASDAQ:ACRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AcelRx Pharmaceuticals (NASDAQ ACRX) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.